Dapagliflozin 10 mg: 7.6% (dapagliflozin plus metformin XR) vs. 11.0% (dapagliflozin plus placebo) or 4.3% (metformin XR plus placebo) There were no major events of hypoglycemia.

Objectives: The efficacy of dapagliflozin as add-on therapy to metformin has been assessed in randomized trials. However, its effectiveness has not been assessed in a US real-world setting.

Scientists at Thomas Jefferson University have made an exciting discovery that could improve the lives of many people with Type 2 diabetes. Their research shows that using two drugs ...

Signs, symptoms and other reports suggestive of genital infections were 14.8% (8.0% in men, 23.3% in women) with dapagliflozin added to metformin compared to 2.9% (0.4% in men, 5.9% in women) with ...

Bristol-Myers Squibb and AstraZeneca announced positive results from a Phase 3 study of dapagliflozin as add-on therapy to metformin for the treatment of type 2 diabetes. This 24-week, randomized ...

Bristol-Myers Squibb and Astra Zeneca announced positive results from a Phase 3 study of dapagliflozin in adults with type 2 diabetes inadequately controlled on metformin monotherapy. The 52-week ...

Xigduo is intended as a twice-daily treatment and is available in 2 strengths: 5-mg dapagliflozin/850-mg metformin, and 5-mg/1000-mg film-coated tablets. The SGLT-2 inhibitors work by reducing ...

Glenmark Pharmaceuticals Limited, a research-led, global pharmaceutical company, has launched in India the first triple-drug fixed-dose combination (FDC) of the widelyused teneligliptin with ...